- The Myeloma Beacon - https://myelomabeacon.org -
CEP-18770
By: Admin; Published: November 4, 2009 @ 11:52 am | Comments Disabled
| Brand Name: | |
| Generic Name: | |
| Code Name: | CEP-18770 |
| Company: | Cephalon |
| FDA Clinical Phase: | 1/2 |
Description:
CEP-18770 is a boronic-acid based proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Animal studies showed that CEP-18770 demonstrated superior activity to Velcade [1] (bortezomib), and it caused fewer side effects during treatment.
Clinical Trials:
For a list of clinical trials studying CEP-18770 for the treatment of multiple myeloma, see ClinicalTrials.gov [2].
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2009/11/04/cep-18770/
URLs in this post:
[1] Velcade: https://myelomabeacon.org/resources/2008/10/15/velcade/
[2] ClinicalTrials.gov: http://clinicaltrials.gov/ct2/results?term=cep-18770&recr=&rslt=&type=&cond=multiple+myeloma&intr=&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.